Torrent Pharmaceuticals Limited

Jaya Abraham

Vivek Mishra

Chaitanya Dutt

Shailesh Deshpande

Jignesh Kotecha

Sunil Sadanand Nadkarni

Amit Kesarwani

Ramesh Chandra Gupta

Anita Chaudhari

Shital Kumar Zambad

Anoop Mathur

Sachin Latad

Vipul Mittal

Manish Patel

Vijay Chauthaiwale

Sanjay Srivastava

Laxmikant Chhipa

Rameshchandra Gupta

Shitalkumar Pukharaj Zambad

Kiran Chaudhari

Ram Gupta

Kapil Khatri

Suryakant Navale

Pradip Mukhopadhyay

Muzaffar Madny

Astha Parmar

Arunkumar Gupta

Manish Parikh

The present invention relates to a pharmaceutical composition of tapentadol for nasal administration. Present invention also relates to the process of preparation of pharmaceutical composition of tapentadol for nasal administration and its use in the treatment of pain.

Pharmaceutical composition of tapentadol for nasal administration

The present invention relates to an intranasal composition, particularly once weekly intranasal composition comprising methylcobalamin and at least one gelling agent and a process for preparation thereof.

Intranasal composition of methylcobalamin

This invention relates to pharmaceutical formulations comprising 1-(2-thien-2'-yl-2-oxo-ethyl)-3-(methanesulfonyl hydrazine carbonyl) pyridinium, its pharmaceutically acceptable salts, salt-cocrystals and co-crystals, particularly 1-(2-thien-2&#x2032;-yl-2-oxo-ethyl)-3-5(methanesulfonyl hydrazine carbonyl) pyridinium chloride. The formulations are suitable for oral administration and also comprise a permeability enhancer or a suitable base or a mixture thereof. The formulations of this invention are for treating diseases associated with advanced glycation end products.

Pharmaceutical formulations

The present invention relates to novel pyridinium compounds, their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to the use of the above mentioned compounds for the preparation of medicament for use as pharmaceuticals.

Pyridinium compounds

Present invention relates to a low dose pharmaceutical composition, preferably oral composition comprising therapeutically effective amount of [(2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H,5H-10-thia-1,4a-diaza-benzo[a]azulene-3-carbonyl)-amino]-acetic acid (compound A) in the range of 2.5 mg to 60 mg. Present invention also relates to a method of treating inflammatory bowel disease in a mammal by administrating said low dose pharmaceutical composition. Further, present invention relates to a use of the compound A for the preparation of low dose pharmaceutical composition for the treatment of inflammatory bowel disease in a mammal.

Low dose pharmaceutical composition

Disclosed herein are pharmaceutical compositions for nasal administration comprising tapentadol, their preparation and their use in the treatment of pain.

Tapentadol nasal composition

Present invention relates to a stable pharmaceutical composition comprising intimate mixture of alogliptin and metformin, and suitable pharmaceutically acceptable excipient/s; wherein metformin is present in about 3.3 parts or more parts by weight relative to 100 parts by weight of the total weight of part comprising alogliptin. Invention also encompasses various processes of preparing said pharmaceutical composition and its use in improving glycemic control in adults with type 2 diabetes mellitus.

Pharmaceutical composition of alogliptin and metformin

The present invention relates to a pharmaceutical composition of tapentadol for parenteral administration which provides prolonged release of tapentadol. Present invention also relates to the process of preparation of pharmaceutical composition of tapentadol for parenteral administration and its use in the treatment of pain.

Pharmaceutical composition of tapentadol for parenteral administration

Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease

The present invention provides a pharmaceutical composition capable of forming in-situ implant comprising goserelin or its pharmaceutically acceptable salts thereof, biodegradable polymer and a biocompatible organic solvent wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid. The present invention further provides a process for the preparation of pharmaceutical composition capable of forming in-situ implant. A kit containing composition for in-situ implant is provided comprising a first vial comprising a composition comprising a biodegradable polymer and a biocompatible organic solvent; wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid; and a second vial comprising goserelin acetate.

Pharmaceutical composition containing goserelin for in-situ implant

The present invention relates to a novel acid addition salt of risperidone, wherein acid counterion is selected from the group consisting of pamoic acid, caproic acid, cypionic acid, decanoic acid, camphor sulfonic acid, enanthic acid, palmitic acid, fusidic acid, gluceptic acid, gluconic acid, lactobionic acid, lauric acid, levulinic acid and valeric acid, a process for the preparation and pharmaceutical composition comprising the same. Further, the invention relates to the use of said pharmaceutical composition comprising the acid addition salt of risperidone in the treatment of patient suffering from psychotic disorders.

Acid addition salts of risperidone and pharmaceutical compositions thereof

Growing community of inventors

Gandhinagar, India

Jaya Abraham